Fig. 4
Oxaliplatin reduces tNOX and SIRT1 expression in p53-wild-type cells but not in p53-null or -mutant cells. a-c, Cell lysates were separated by SDS-PAGE and analyzed by Western blotting. β-Actin was used as an internal control. Representative images are shown. d, tNOX was knocked down by RNA interference in p53-null cells. The cells were treated with ddH2O or oxaliplatin for 24 h, and the percentage of apoptotic cells was determined by flow cytometry. The presented values (mean ± SEs) represent at least three independent experiments (*p < 0.05 or **p < 0.01 for tNOX-knockdown cells vs. controls). Representative images are shown